SK287577B6 - Kompozícia s regulovaným uvoľňovaním, spôsob jej výroby a farmaceutický prípravok obsahujúci kompozíciu - Google Patents

Kompozícia s regulovaným uvoľňovaním, spôsob jej výroby a farmaceutický prípravok obsahujúci kompozíciu Download PDF

Info

Publication number: SK287577B6
Authority: SK; Slovakia
Prior art keywords: controlled release; lactic acid; weight; release composition; less
Prior art date: 2001-06-29

Application number

SK1560-2003A

Other languages

English (en)

Slovak (sk)

Other versions

SK15602003A3 (sk

Inventor

Kazumichi Yamamoto

Akiko Yamada

Yoshio Hata

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-29

Filing date

2002-06-28

Publication date

2011-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287577(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-28 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2004-06-08 Publication of SK15602003A3 publication Critical patent/SK15602003A3/sk

2011-03-04 Publication of SK287577B6 publication Critical patent/SK287577B6/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 76
238000013270 controlled release Methods 0.000 title claims abstract description 52
238000004519 manufacturing process Methods 0.000 title claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 152
229920000642 polymer Polymers 0.000 claims abstract description 107
239000004310 lactic acid Substances 0.000 claims abstract description 72
235000014655 lactic acid Nutrition 0.000 claims abstract description 72
238000000034 method Methods 0.000 claims abstract description 49
150000003839 salts Chemical class 0.000 claims abstract description 33
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims abstract description 18
206010006187 Breast cancer Diseases 0.000 claims abstract description 14
208000026310 Breast neoplasm Diseases 0.000 claims abstract description 14
206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 7
201000009273 Endometriosis Diseases 0.000 claims abstract description 7
206010060862 Prostate cancer Diseases 0.000 claims abstract description 7
208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 7
206010046798 Uterine leiomyoma Diseases 0.000 claims abstract description 7
230000002028 premature Effects 0.000 claims abstract description 7
230000003449 preventive effect Effects 0.000 claims abstract description 7
210000002307 prostate Anatomy 0.000 claims abstract description 7
239000003433 contraceptive agent Substances 0.000 claims abstract description 5
201000010260 leiomyoma Diseases 0.000 claims abstract description 5
239000013543 active substance Substances 0.000 claims description 43
239000002904 solvent Substances 0.000 claims description 33
108090000765 processed proteins & peptides Proteins 0.000 claims description 18
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
239000011259 mixed solution Substances 0.000 claims description 7
206010020718 hyperplasia Diseases 0.000 claims description 5
206010057654 Breast cancer female Diseases 0.000 claims description 4
125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 claims description 4
125000002437 D-histidyl group Chemical group N[C@@H](C(=O)*)CC=1N=CNC1 0.000 claims description 3
125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 3
229940124558 contraceptive agent Drugs 0.000 claims description 3
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 2
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
239000003814 drug Substances 0.000 abstract description 19
238000013268 sustained release Methods 0.000 abstract description 6
239000012730 sustained-release form Substances 0.000 abstract description 6
208000005171 Dysmenorrhea Diseases 0.000 abstract description 4
208000010579 uterine corpus leiomyoma Diseases 0.000 abstract description 4
201000007954 uterine fibroid Diseases 0.000 abstract description 4
206010067269 Uterine fibrosis Diseases 0.000 abstract description 3
230000002254 contraceptive effect Effects 0.000 abstract description 2
230000001225 therapeutic effect Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
229960000448 lactic acid Drugs 0.000 description 69
239000000243 solution Substances 0.000 description 57
239000003094 microcapsule Substances 0.000 description 46
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
229920002988 biodegradable polymer Polymers 0.000 description 27
239000004621 biodegradable polymer Substances 0.000 description 27
239000003960 organic solvent Substances 0.000 description 26
239000003795 chemical substances by application Substances 0.000 description 20
239000000839 emulsion Substances 0.000 description 20
239000000047 product Substances 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
229930195725 Mannitol Natural products 0.000 description 14
238000010438 heat treatment Methods 0.000 description 14
238000006460 hydrolysis reaction Methods 0.000 description 14
239000000594 mannitol Substances 0.000 description 14
235000010355 mannitol Nutrition 0.000 description 14
108010091748 peptide A Proteins 0.000 description 14
239000012071 phase Substances 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
239000008346 aqueous phase Substances 0.000 description 13
230000007062 hydrolysis Effects 0.000 description 13
150000001298 alcohols Chemical class 0.000 description 12
239000012153 distilled water Substances 0.000 description 12
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 12
238000001035 drying Methods 0.000 description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
230000001419 dependent effect Effects 0.000 description 10
230000003204 osmotic effect Effects 0.000 description 10
-1 pamoates Chemical class 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
239000002585 base Substances 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
229940079593 drug Drugs 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
239000000126 substance Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 8
239000006185 dispersion Substances 0.000 description 8
239000003163 gonadal steroid hormone Substances 0.000 description 8
150000008282 halocarbons Chemical class 0.000 description 8
239000000463 material Substances 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 7
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 7
238000006116 polymerization reaction Methods 0.000 description 7
239000000843 powder Substances 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 6
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
239000008112 carboxymethyl-cellulose Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000005227 gel permeation chromatography Methods 0.000 description 5
239000004005 microsphere Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
239000008096 xylene Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
239000004372 Polyvinyl alcohol Substances 0.000 description 4
241000700159 Rattus Species 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
229920002451 polyvinyl alcohol Polymers 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
206010001928 Amenorrhoea Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
206010036618 Premenstrual syndrome Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000002495 Uterine Neoplasms Diseases 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
239000010419 fine particle Substances 0.000 description 3
230000009477 glass transition Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
150000002772 monosaccharides Chemical class 0.000 description 3
150000002482 oligosaccharides Chemical class 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000001694 spray drying Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
206010046766 uterine cancer Diseases 0.000 description 3
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
108700012941 GNRH1 Proteins 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
235000009697 arginine Nutrition 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
150000004292 cyclic ethers Chemical class 0.000 description 2
NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000010528 free radical solution polymerization reaction Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
150000002402 hexoses Chemical class 0.000 description 2
238000002372 labelling Methods 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
238000005259 measurement Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000010791 quenching Methods 0.000 description 2
239000002994 raw material Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
DFZVZEMNPGABKO-SSDOTTSWSA-N (2r)-2-amino-3-pyridin-3-ylpropanoic acid Chemical group OC(=O)[C@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-SSDOTTSWSA-N 0.000 description 1
XIGSAGMEBXLVJJ-RXMQYKEDSA-N (2r)-2-azaniumyl-6-(carbamoylamino)hexanoate Chemical group NC(=O)NCCCC[C@@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-RXMQYKEDSA-N 0.000 description 1
AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical group CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 description 1
RNQVQPAWYYPLDK-VIFPVBQESA-N (2s)-6-[carbamimidoyl(ethyl)amino]-2-(ethylamino)hexanoic acid Chemical group CCN[C@H](C(O)=O)CCCCN(CC)C(N)=N RNQVQPAWYYPLDK-VIFPVBQESA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AWIOOXLYLWTJMX-UHFFFAOYSA-N 2-(oxolane-2-carbonylamino)acetic acid Chemical group OC(=O)CNC(=O)C1CCCO1 AWIOOXLYLWTJMX-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical group C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 1
DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 description 1
RHGKLRLOHDJJDR-SCSAIBSYSA-N D-citrulline Chemical group OC(=O)[C@H](N)CCCNC(N)=O RHGKLRLOHDJJDR-SCSAIBSYSA-N 0.000 description 1
RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical group OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
238000009835 boiling Methods 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000012662 bulk polymerization Methods 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
108700008462 cetrorelix Proteins 0.000 description 1
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
229960003230 cetrorelix Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
150000004699 copper complex Chemical class 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000004388 gamma ray sterilization Methods 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000002474 gonadorelin antagonist Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002736 metal compounds Chemical class 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229940078552 o-xylene Drugs 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
238000007151 ring opening polymerisation reaction Methods 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
IXXMVXXFAJGOQO-UHFFFAOYSA-N tert-butyl 2-hydroxypropanoate Chemical compound CC(O)C(=O)OC(C)(C)C IXXMVXXFAJGOQO-UHFFFAOYSA-N 0.000 description 1
150000003538 tetroses Chemical class 0.000 description 1
230000007704 transition Effects 0.000 description 1
VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 1
150000003641 trioses Chemical class 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000012795 verification Methods 0.000 description 1
PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
CHJMFFKHPHCQIJ-UHFFFAOYSA-L zinc;octanoate Chemical compound [Zn+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O CHJMFFKHPHCQIJ-UHFFFAOYSA-L 0.000 description 1
FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pregnancy & Childbirth (AREA)
Zoology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Lubricants (AREA)
Moulds For Moulding Plastics Or The Like (AREA)

SK1560-2003A 2001-06-29 2002-06-28 Kompozícia s regulovaným uvoľňovaním, spôsob jej výroby a farmaceutický prípravok obsahujúci kompozíciu SK287577B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2001199484		2001-06-29
JP2001340993		2001-11-06
PCT/JP2002/006527 WO2003002092A2 (fr)	2001-06-29	2002-06-28	Composition a liberation controlee et procede de production de cette composition

Publications (2)

Publication Number	Publication Date
SK15602003A3 SK15602003A3 (sk)	2004-06-08
SK287577B6 true SK287577B6 (sk)	2011-03-04

Family

ID=26617910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1560-2003A SK287577B6 (sk)	2001-06-29	2002-06-28	Kompozícia s regulovaným uvoľňovaním, spôsob jej výroby a farmaceutický prípravok obsahujúci kompozíciu

Country Status (34)

Country	Link
US (4)	US7429559B2 (fr)
EP (3)	EP1330293B2 (fr)
JP (5)	JP2003206240A (fr)
KR (2)	KR100916173B1 (fr)
CN (3)	CN1292796C (fr)
AR (2)	AR034641A1 (fr)
AT (3)	ATE326264T1 (fr)
AU (2)	AU2002311631B2 (fr)
BR (1)	BRPI0210561B8 (fr)
CA (1)	CA2455392C (fr)
CO (1)	CO5540367A2 (fr)
CR (1)	CR11283A (fr)
CY (2)	CY1105071T1 (fr)
CZ (1)	CZ306327B6 (fr)
DE (2)	DE60211464T3 (fr)
DK (2)	DK1949936T3 (fr)
ES (2)	ES2366677T3 (fr)
HK (1)	HK1056332A1 (fr)
HU (1)	HU230351B1 (fr)
IL (3)	IL159059A0 (fr)
MX (1)	MXPA03011456A (fr)
MY (1)	MY142066A (fr)
NO (1)	NO331883B1 (fr)
NZ (2)	NZ541884A (fr)
PE (1)	PE20030066A1 (fr)
PL (1)	PL204903B1 (fr)
PT (2)	PT1949936E (fr)
RU (1)	RU2301661C2 (fr)
SG (1)	SG180015A1 (fr)
SI (1)	SI1949936T1 (fr)
SK (1)	SK287577B6 (fr)
TW (2)	TWI332407B (fr)
WO (1)	WO2003002092A2 (fr)
ZA (1)	ZA200309152B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL136951A0 (en) *	1998-01-16	2001-06-14	Takeda Chemical Industries Ltd	Sustained-release composition, method of its production and use thereof
TWI332407B (en) *	2001-06-29	2010-11-01	Takeda Chemical Industries Ltd	Controlled release composition and method of producting the same
TWI225416B (en) *	2001-06-29	2004-12-21	Takeda Chemical Industries Ltd	Sustained-release composition and process for producing the same
KR101139112B1 (ko) *	2002-06-25	2012-04-30	다케다 야쿠힌 고교 가부시키가이샤	서방성 조성물의 제조 방법
US20070207211A1 (en) *	2003-04-10	2007-09-06	Pr Pharmaceuticals, Inc.	Emulsion-based microparticles and methods for the production thereof
BRPI0409032A (pt)	2003-04-10	2006-05-02	Pr Pharmaceuticals	método para a produção de micropartìculas à base de emulsão
US8871269B2 (en) *	2003-07-15	2014-10-28	Evonik Corporation	Method for the preparation of controlled release formulations
US8900636B2 (en) *	2003-07-23	2014-12-02	Evonik Corporation	Controlled release compositions
TW200529890A (en)	2004-02-10	2005-09-16	Takeda Pharmaceutical	Sustained-release preparations
TW200613012A (en) *	2004-07-02	2006-05-01	Takeda Pharmaceuticals Co	Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) *	2005-05-09	2006-11-09	Mcintyre Jon T	Method for treatment of uterine fibroid tumors
US20070149457A1 (en) *	2005-12-13	2007-06-28	Byron Rubin	Stable solid forms of enterostatin
KR20150017777A (ko)	2006-01-18	2015-02-17	포시에이서 파마슈티컬스 인코포레이티드	안정성이 강화된 약학 조성물
US7858663B1 (en) *	2007-10-31	2010-12-28	Pisgah Laboratories, Inc.	Physical and chemical properties of thyroid hormone organic acid addition salts
CN101563068B (zh)	2006-12-18	2013-03-20	武田药品工业株式会社	缓释组合物和其制备方法
US20110319987A1 (en) *	2009-05-20	2011-12-29	Arsenal Medical	Medical implant
KR101811797B1 (ko) *	2013-04-03	2017-12-22	동국제약 주식회사	도네페질을 포함하는 비경구투여용 약제학적 조성물
JP6564369B2 (ja)	2013-12-09	2019-08-21	デュレクトコーポレイション	薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CN103751851A (zh) *	2014-01-17	2014-04-30	东华大学	一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) *	2014-04-07	2015-10-07	에스케이케미칼주식회사	약물함유 고분자미립구 제조방법
CN106456704A (zh)	2014-04-16	2017-02-22	Veyx-药物有限公司	兽药组合物和其应用
US10787920B2 (en)	2016-10-12	2020-09-29	General Electric Company	Turbine engine inducer assembly
KR102089737B1 (ko)	2017-11-01	2020-03-16	한국화학연구원	에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
WO2024095158A1 (fr)	2022-10-31	2024-05-10	Takeda Pharmaceutical Company Limited	Dosage d'agonistes du récepteur de type 2 de l'orexine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3297033A (en)	1963-10-31	1967-01-10	American Cyanamid Co	Surgical sutures
US3565869A (en)	1968-12-23	1971-02-23	American Cyanamid Co	Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3755558A (en)	1971-02-23	1973-08-28	Du Pont	Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en)	1971-11-22	1974-10-01	Ethicon Inc	Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en)	1973-05-03	1975-10-14	American Cyanamid Co	Process for polymerizing a substantially pure glycolide composition
US3890283A (en)	1973-06-04	1975-06-17	American Cyanamid Co	Process for post-polymerizing polyglycolic acid
US4258063A (en)	1978-06-23	1981-03-24	Henkel Corporation	Self-emulsifying cosmetic base
US4249531A (en)	1979-07-05	1981-02-10	Alza Corporation	Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en)	1979-09-12	1981-06-16	Eli Lilly And Company	Polymerization process and product
PH19942A (en)	1980-11-18	1986-08-14	Sintex Inc	Microencapsulation of water soluble polypeptides
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4479911A (en)	1982-01-28	1984-10-30	Sandoz, Inc.	Process for preparation of microspheres and modification of release rate of core material
US4605730A (en)	1982-10-01	1986-08-12	Ethicon, Inc.	Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en)	1982-11-08	1985-09-10	Johnson & Johnson Products, Inc.	Absorbable bone fixation device
FR2537980B1 (fr)	1982-12-17	1986-12-19	Sandoz Sa	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de)	1983-08-26	1986-07-31	Sandoz Ag	Polyolester, deren herstellung und verwendung.
JPS60100516A (ja)	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
JPH0678425B2 (ja)	1984-07-06	1994-10-05	和光純薬工業株式会社	重合体の新規製造法
CA1256638A (fr)	1984-07-06	1989-06-27	Motoaki Tanaka	Polymere, et sa production
DE3678308D1 (de)	1985-02-07	1991-05-02	Takeda Chemical Industries Ltd	Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja)	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
ATE168391T1 (de) *	1990-04-13	1998-08-15	Takeda Chemical Industries Ltd	Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
JP3277342B2 (ja)	1992-09-02	2002-04-22	武田薬品工業株式会社	徐放性マイクロカプセルの製造法
US5353086A (en) *	1993-05-03	1994-10-04	Eastman Kodak Company	Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) *	1993-12-09	2007-01-11	Zentaris Gmbh	Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3490171B2 (ja)	1994-02-21	2004-01-26	武田薬品工業株式会社	生体内分解性ポリマーの末端カルボキシル基におけるエステル
US5594091A (en)	1994-02-21	1997-01-14	Takeda Chemical Industries, Ltd.	Matrix for sustained-release preparation
US5763513A (en)	1994-05-19	1998-06-09	Mitsui Toatsu Chemicals, Inc.	L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) *	1995-01-23	1996-10-08	Takeda Chem Ind Ltd	徐放性製剤の製造法
JP3902272B2 (ja) *	1995-09-04	2007-04-04	武田薬品工業株式会社	徐放性製剤の製造法
US5922662A (en) *	1996-08-07	1999-07-13	Colgate Palmolive Company	High foaming nonionic surfactant based liquid detergent
ES2221019T3 (es)	1996-10-31	2004-12-16	Takeda Chemical Industries, Ltd.	Preparacion de liberacion mantenida.
JPH10273447A (ja) *	1997-01-29	1998-10-13	Takeda Chem Ind Ltd	徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (fr)	1997-01-29	1998-07-30	Takeda Chemical Industries, Ltd.	Microspheres a liberation prolongee, leur production et utilisation
IL136951A0 (en) *	1998-01-16	2001-06-14	Takeda Chemical Industries Ltd	Sustained-release composition, method of its production and use thereof
JPH11269094A (ja)	1998-01-16	1999-10-05	Takeda Chem Ind Ltd	徐放性組成物、その製造法および用途
US6114495A (en)	1998-04-01	2000-09-05	Cargill Incorporated	Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en)	1998-10-28	2003-05-20	Atrix Laboratories	Polymeric delivery formulations of leuprolide with improved efficacy
DE69923795T2 (de)	1998-12-15	2006-03-16	Takeda Pharmaceutical Co. Ltd.	Verfahren zur Herstellung biologisch-abbaubarer Polyester
JP2000238051A (ja) †	1999-02-23	2000-09-05	Kansei Corp	表皮シートの発泡成形型へのセッティング方法
BR0012400A (pt)	1999-07-15	2002-05-21	Takeda Chemical Industries Ltd	Composição de liberação continuada, método para produzir composição de liberação continuada, medicamento, e, agente profilático ou terapeutico
JP2001081043A (ja) *	1999-07-15	2001-03-27	Takeda Chem Ind Ltd	徐放性組成物、その製造法および用途
JP3837607B2 (ja) †	2000-05-29	2006-10-25	Ｔｃｍ株式会社	マスト用溶接位置決め治具
PT1693054T (pt)	2000-08-07	2016-07-07	Takeda Pharmaceuticals Co	Polímero de ácido láctico e processo para a sua produção
AU2002218494A1 (en) *	2000-11-29	2002-06-11	Takeda Chemical Industries Ltd.	Medicinal compositions and process for producing the same
AU2002221139A1 (en) *	2000-12-15	2002-06-24	Takeda Chemical Industries Ltd.	Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TWI332407B (en) *	2001-06-29	2010-11-01	Takeda Chemical Industries Ltd	Controlled release composition and method of producting the same

2002
- 2002-06-26 TW TW091114000A patent/TWI332407B/zh not_active IP Right Cessation
- 2002-06-26 AR ARP020102406A patent/AR034641A1/es not_active Application Discontinuation
- 2002-06-26 TW TW094113186A patent/TW200526267A/zh unknown
- 2002-06-27 PE PE2002000578A patent/PE20030066A1/es active IP Right Grant
- 2002-06-28 EP EP02738838A patent/EP1330293B2/fr not_active Expired - Lifetime
- 2002-06-28 ES ES08003261T patent/ES2366677T3/es not_active Expired - Lifetime
- 2002-06-28 SG SG2005085675A patent/SG180015A1/en unknown
- 2002-06-28 JP JP2002189247A patent/JP2003206240A/ja active Pending
- 2002-06-28 AT AT02738838T patent/ATE326264T1/de active
- 2002-06-28 DK DK08003261.8T patent/DK1949936T3/da active
- 2002-06-28 HU HU0400378A patent/HU230351B1/hu unknown
- 2002-06-28 CA CA2455392A patent/CA2455392C/fr not_active Expired - Fee Related
- 2002-06-28 SK SK1560-2003A patent/SK287577B6/sk unknown
- 2002-06-28 BR BR0210561-6 patent/BRPI0210561B8/pt not_active IP Right Cessation
- 2002-06-28 PT PT08003261T patent/PT1949936E/pt unknown
- 2002-06-28 RU RU2004102507/15A patent/RU2301661C2/ru active
- 2002-06-28 ES ES02738838T patent/ES2263788T5/es not_active Expired - Lifetime
- 2002-06-28 AT AT08003261T patent/ATE509668T1/de active
- 2002-06-28 CN CNB028130618A patent/CN1292796C/zh not_active Expired - Lifetime
- 2002-06-28 DK DK02738838.8T patent/DK1330293T4/da active
- 2002-06-28 EP EP08003261A patent/EP1949936B1/fr not_active Expired - Lifetime
- 2002-06-28 CN CN200610093268A patent/CN100577206C/zh not_active Expired - Fee Related
- 2002-06-28 KR KR1020037017129A patent/KR100916173B1/ko active IP Right Grant
- 2002-06-28 PT PT02738838T patent/PT1330293E/pt unknown
- 2002-06-28 MX MXPA03011456A patent/MXPA03011456A/es active IP Right Grant
- 2002-06-28 PL PL367518A patent/PL204903B1/pl unknown
- 2002-06-28 KR KR1020097001485A patent/KR100961413B1/ko not_active IP Right Cessation
- 2002-06-28 AT AT04076939T patent/ATE387937T1/de not_active IP Right Cessation
- 2002-06-28 NZ NZ541884A patent/NZ541884A/en not_active IP Right Cessation
- 2002-06-28 SI SI200230949T patent/SI1949936T1/sl unknown
- 2002-06-28 MY MYPI20022474A patent/MY142066A/en unknown
- 2002-06-28 DE DE60211464T patent/DE60211464T3/de not_active Expired - Lifetime
- 2002-06-28 DE DE60225481T patent/DE60225481T2/de not_active Expired - Lifetime
- 2002-06-28 AU AU2002311631A patent/AU2002311631B2/en not_active Expired
- 2002-06-28 EP EP04076939A patent/EP1491236B1/fr not_active Expired - Lifetime
- 2002-06-28 US US10/182,731 patent/US7429559B2/en not_active Expired - Fee Related
- 2002-06-28 IL IL15905902A patent/IL159059A0/xx unknown
- 2002-06-28 CZ CZ2003-3493A patent/CZ306327B6/cs not_active IP Right Cessation
- 2002-06-28 NZ NZ529969A patent/NZ529969A/en not_active IP Right Cessation
- 2002-06-28 WO PCT/JP2002/006527 patent/WO2003002092A2/fr active Application Filing
- 2002-06-28 CN CNB2005100896706A patent/CN100348265C/zh not_active Expired - Fee Related
2003
- 2003-11-25 IL IL159059A patent/IL159059A/en active IP Right Grant
- 2003-11-25 ZA ZA2003/09152A patent/ZA200309152B/en unknown
- 2003-11-27 HK HK03108668A patent/HK1056332A1/xx not_active IP Right Cessation
- 2003-12-19 NO NO20035738A patent/NO331883B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111729A patent/CO5540367A2/es active IP Right Grant
2004
- 2004-04-13 JP JP2004117981A patent/JP2004238400A/ja not_active Withdrawn
2006
- 2006-07-07 CY CY20061100943T patent/CY1105071T1/el unknown
- 2006-12-01 AU AU2006246508A patent/AU2006246508B2/en not_active Ceased
2007
- 2007-10-18 IL IL186782A patent/IL186782A0/en unknown
2008
- 2008-07-29 US US12/181,472 patent/US8067030B2/en not_active Expired - Fee Related
2009
- 2009-03-18 JP JP2009065612A patent/JP2009167203A/ja not_active Withdrawn
2010
- 2010-02-18 CR CR11283A patent/CR11283A/es unknown
- 2010-04-26 JP JP2010101264A patent/JP4819172B2/ja not_active Expired - Lifetime
- 2010-04-26 JP JP2010101265A patent/JP4819173B2/ja not_active Expired - Lifetime
2011
- 2011-03-16 US US13/064,282 patent/US8246987B2/en not_active Expired - Fee Related
- 2011-07-15 CY CY20111100692T patent/CY1111708T1/el unknown
2012
- 2012-07-13 US US13/548,463 patent/US8815801B2/en not_active Expired - Lifetime
2014
- 2014-11-03 AR ARP140104096A patent/AR098261A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20110166084A1 (en)	2011-07-07
DE60211464T3 (de)	2011-03-17
NO331883B1 (no)	2012-04-23
NZ541884A (en)	2007-01-26
US20090005318A1 (en)	2009-01-01
BRPI0210561B1 (pt)	2018-08-14
MY142066A (en)	2010-08-30
ATE509668T1 (de)	2011-06-15
ZA200309152B (en)	2005-01-26
NO20035738D0 (no)	2003-12-19
CY1111708T1 (el)	2015-10-07
RU2301661C2 (ru)	2007-06-27
HU230351B1 (hu)	2016-02-29
KR100961413B1 (ko)	2010-06-09
WO2003002092A2 (fr)	2003-01-09
CN1868458A (zh)	2006-11-29
SI1949936T1 (sl)	2011-08-31
CN1724066A (zh)	2006-01-25
JP2010189427A (ja)	2010-09-02
NO20035738L (no)	2004-02-27
CZ306327B6 (cs)	2016-12-07
PT1330293E (pt)	2006-08-31
CN100348265C (zh)	2007-11-14
MXPA03011456A (es)	2004-07-01
AR098261A2 (es)	2016-05-18
US7429559B2 (en)	2008-09-30
RU2004102507A (ru)	2005-03-10
PT1949936E (pt)	2011-07-12
IL159059A0 (en)	2004-05-12
US20120283187A1 (en)	2012-11-08
AU2002311631B2 (en)	2007-02-08
CA2455392A1 (fr)	2003-01-09
BRPI0210561B8 (pt)	2021-05-25
TWI332407B (en)	2010-11-01
CR11283A (es)	2010-05-31
ES2366677T3 (es)	2011-10-24
DE60225481T2 (de)	2009-02-26
CY1105071T1 (el)	2010-03-03
EP1491236A1 (fr)	2004-12-29
ATE326264T1 (de)	2006-06-15
CA2455392C (fr)	2011-11-22
DE60225481D1 (de)	2008-04-17
KR20040018402A (ko)	2004-03-03
EP1949936A3 (fr)	2008-10-08
US20030134800A1 (en)	2003-07-17
WO2003002092A3 (fr)	2003-04-10
JP2003206240A (ja)	2003-07-22
NZ529969A (en)	2005-10-28
CN1292796C (zh)	2007-01-03
BR0210561A (pt)	2004-06-22
DK1330293T4 (da)	2011-01-10
KR20090020708A (ko)	2009-02-26
DK1949936T3 (da)	2011-08-15
IL186782A0 (en)	2008-02-09
JP2004238400A (ja)	2004-08-26
SK15602003A3 (sk)	2004-06-08
AU2006246508B2 (en)	2008-09-04
HUP0400378A3 (en)	2010-01-28
HK1056332A1 (en)	2004-02-13
IL159059A (en)	2011-06-30
DK1330293T3 (da)	2006-09-11
PE20030066A1 (es)	2003-03-20
DE60211464T2 (de)	2006-09-07
CN100577206C (zh)	2010-01-06
JP2009167203A (ja)	2009-07-30
CN1535168A (zh)	2004-10-06
TW200526267A (en)	2005-08-16
CZ20033493A3 (cs)	2004-08-18
CO5540367A2 (es)	2005-07-29
EP1330293B1 (fr)	2006-05-17
JP4819172B2 (ja)	2011-11-24
KR100916173B1 (ko)	2009-09-08
US8067030B2 (en)	2011-11-29
US8815801B2 (en)	2014-08-26
PL367518A1 (pl)	2005-02-21
EP1330293A2 (fr)	2003-07-30
SG180015A1 (en)	2012-05-30
EP1949936A2 (fr)	2008-07-30
US8246987B2 (en)	2012-08-21
PL204903B1 (pl)	2010-02-26
JP2010189428A (ja)	2010-09-02
EP1949936B1 (fr)	2011-05-18
EP1491236B1 (fr)	2008-03-05
AU2006246508A1 (en)	2006-12-21
JP4819173B2 (ja)	2011-11-24
AR034641A1 (es)	2004-03-03
ATE387937T1 (de)	2008-03-15
DE60211464D1 (de)	2006-06-22
EP1330293B2 (fr)	2010-10-27
HUP0400378A2 (hu)	2004-12-28
ES2263788T5 (es)	2011-02-22
ES2263788T3 (es)	2006-12-16

Publication	Publication Date	Title
US8246987B2 (en)	2012-08-21	Controlled release composition and method of producing the same
JP5931147B2 (ja)	2016-06-08	徐放性組成物およびその製造法
AU2002311631A1 (en)	2003-05-15	Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
JP2004256546A (ja)	2004-09-16	徐放性組成物およびその製造法